Arrowhead Pharmaceuticals vs Axsome Therapeutics

Arrowhead Pharmaceuticals (ARWR), health care, and Axsome Therapeutics (AXSM), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Axsome Therapeutics is worth $7.2B on the stock market and Arrowhead Pharmaceuticals $6.1B: Axsome Therapeutics is valued at 18% more. Arrowhead Pharmaceuticals's operating margin in its latest fiscal year was 11.9% and Axsome Therapeutics's -26.1%. Over the past year Arrowhead Pharmaceuticals's share price has moved +9.24% and Axsome Therapeutics's -7.10%.

Key facts

Arrowhead Pharmaceuticals market value
$6.1B
Axsome Therapeutics market value
$7.2B
Arrowhead Pharmaceuticals revenue
$829.4MFY to 2025-09-30
Axsome Therapeutics revenue
$638.5MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Arrowhead Pharmaceuticals vs Axsome Therapeutics: every measure side by side
Measure Arrowhead Pharmaceuticals Axsome Therapeutics
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-09-302025-12-31
Size
Market cap$6.1Blower$7.2Bhigher
Revenue$829.4Mhigher$638.5Mlower
Earnings-$1.6Mhigher-$183.2Mlower
Employees711lower1,390higher
Total assets$1.4Bhigher$689.8Mlower
Valuation
P/E——
P/S7.3lower11.2higher
P/B121higher67.8lower
Dividend yield0.00%0.00%
Profitability
Operating margin11.9%higher-26.1%lower
Balance sheet
Net assets$466.1Mhigher$88.3Mlower
Total liabilities$881.9Mhigher$601.5Mlower
Total debt—$187.7M
Cash on hand$226.5Mlower$322.9Mhigher
Price change
Today-2.76%lower-0.77%higher
1 year+9.24%higher-7.10%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Arrowhead Pharmaceuticals only (2)

Axsome Therapeutics only (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio. Who owns ARWR · Who owns AXSM

Further comparisons

Learn

Questions and answers

Which is bigger, Arrowhead Pharmaceuticals or Axsome Therapeutics?

By market value, Axsome Therapeutics is the larger: $7.2B against $6.1B for Arrowhead Pharmaceuticals. By revenue in its latest fiscal year, Arrowhead Pharmaceuticals is the larger: $829.4M against $638.5M for Axsome Therapeutics.

Which has the higher operating margin?

Arrowhead Pharmaceuticals: 11.9%, against -26.1% for Axsome Therapeutics. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Arrowhead Pharmaceuticals and Axsome Therapeutics?

None of the tracked superinvestors holds both in their latest 13F filing. 2 hold Arrowhead Pharmaceuticals and 0 hold Axsome Therapeutics.

Cite this page

Funkfolio, “Arrowhead Pharmaceuticals vs Axsome Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/arwr-vs-axsm

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.